Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Phacotrabeculectomy with collagen matrix implant (Ologen®) versus mitomycin C augmented phacotrabeculectomy: clinical results of a prospective randomized trial

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Presented Poster Session: Glaucoma

Session Date/Time: Monday 07/09/2015 | 09:30-11:00

Paper Time: 09:30

Venue: Poster Village: Pod 4

First Author: : A.Wlaz POLAND

Co Author(s): :    A. Wilkos-Kuc   A. Rozegnal-Madej   T. Zarnowski        

Abstract Details

Purpose:

To assess the efficacy and safety of collagen matrix implant (Ologen®; OLO) in phacotrabeculectomy and to compare with mitomycin C (MMC) augmented phacotrabeculectomy.

Setting:

Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin, Poland

Methods:

Prospective randomized comparative study of 20 eyes (20 patients) with primary open angle glaucoma (POAG) (13 eyes) and pseudoexfoliation (PEX) glaucoma (PEXG) (7 eyes) in the follow-up of 3 months. All patients were randomized and underwent phacotrabeculectomy augmented with OLO (12 eyes) or MMC (8 eyes). Main outcome measures: intraocular pressure (IOP), best corrected visual acuity (BCVA; LogMAR), filtering bleb score (Moorfields bleb grading system; MBGS), number of antiglaucoma drugs, visual field and cataract grading (the lens opacities classification system III; LOCS III).

Results:

At 3 months after surgery: 1. In the OLO group mean IOP decreased from 30.75 ± 7.78 mmHg on 1.25 drugs to 13.5 ± 4.87 mmHg on 0.5 medications (56.1% reduction). In the MMC group IOP decreased from 33.25 ± 10.96 mmHg on 0.63 drugs to 13.75 ± 3.58 mmHg on 0.25 medications (58.6% reduction). 2. Mean height of the bleb in the OLO and MMC group was 2.83 and 2.13 (MBGS), respectively (P = 0.01). 3. Mean BCVA in the OLO and MMC group improved from 0.42 to 0.36 and from 0.69 to 0.28, respectively.

Conclusions:

1. According to our results, OLO implant could be a new, safe and effective alternative to MMC with similar success rate at 3 months of follow-up. Further trials and longer observation are required to reveal differences between these two adjuvants. 2. There was statistically significant decrease in IOP postoperatively in both surgical groups without significant intergroup differences (P = 0.001; Student’s t-test). 3. In both groups there was BCVA improvement. There were no statistically significant intergroup differences. 4. At 3 months after surgery, the blebs in OLO eyes were higher than in MMC eyes (P=0.009; Mann-Whitney U test).

Financial Disclosure:

NONE

Back to previous